Wiggins, Simon join C-suite at Vaxcyte

Vaccine play Vaxcyte Inc. (NASDAQ:PCVX) bolstered its C-suite with the addition of Mark Wiggins as chief business officer (CBO) and Jakub Simon as CMO. Wiggins, a former EVP of business development at Biogen Idec Inc., was most recently CBO of Tracon Pharmaceuticals Inc. (NASDAQ:TCON). Simon, who has been consulting for Vaxcyte, was director of clinical research for vaccines at Merck & Co. Inc. (NYSE:MRK).

After battling it out in the courts, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and AstraZeneca plc (LSE:AZN; NASDAQ:AZN) have reached an agreement for Chris Sheldon to join GSK, where he will become SVP of commercial portfolio, according to a GSK spokesperson. At AZ, Sheldon has held leadership roles for nearly two decades years. ...